Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3K? isoform.

ABSTRACT: Development of novel PI3K inhibitors is an important strategy to overcome their resistance and poor tolerability in clinical trials. The quassinoid family member Brusatol shows specific inhibitory activity against hematologic malignancies. However, the mechanism of its anti-cancer activity is unknown. We investigated the anti-cancer activity of Brusatol on multiple hematologic malignancies derived cell lines. The results demonstrated that the PI3K? isoform was identified as a direct target of Brusatol, and inhibition was dramatically reduced on cells with lower PI3K? levels. Novel synthetic analogs were also developed and tested in vitro and in vivo. They shared comparable or superior potency in their ability to inhibit malignant hematologic cell lines, and in a xenograft transplant mouse model. One unique analog had minimal toxicity to normal human cells and in a mouse model. These new analogs have enhanced potential for development as a new class of PI3K inhibitors for treatment of hematologic malignancies.

SUBMITTER: Pei Y 

PROVIDER: S-EPMC7253423 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature